Public Sector Pension Investment Board lifted its position in Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH - Free Report) by 27.2% in the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 118,885 shares of the company's stock after purchasing an additional 25,455 shares during the quarter. Public Sector Pension Investment Board owned 0.25% of Amphastar Pharmaceuticals worth $3,446,000 at the end of the most recent reporting period.
Other large investors have also recently bought and sold shares of the company. GAMMA Investing LLC increased its stake in shares of Amphastar Pharmaceuticals by 4,151.3% in the first quarter. GAMMA Investing LLC now owns 38,644 shares of the company's stock valued at $1,120,000 after buying an additional 37,735 shares in the last quarter. Cambridge Investment Research Advisors Inc. increased its stake in shares of Amphastar Pharmaceuticals by 14.0% in the first quarter. Cambridge Investment Research Advisors Inc. now owns 13,790 shares of the company's stock valued at $400,000 after buying an additional 1,694 shares in the last quarter. Deutsche Bank AG increased its stake in shares of Amphastar Pharmaceuticals by 46.6% in the fourth quarter. Deutsche Bank AG now owns 34,082 shares of the company's stock valued at $1,265,000 after buying an additional 10,839 shares in the last quarter. Picton Mahoney Asset Management increased its stake in shares of Amphastar Pharmaceuticals by 6,600.0% in the first quarter. Picton Mahoney Asset Management now owns 1,608 shares of the company's stock valued at $46,000 after buying an additional 1,584 shares in the last quarter. Finally, ProShare Advisors LLC increased its stake in shares of Amphastar Pharmaceuticals by 27.2% in the fourth quarter. ProShare Advisors LLC now owns 13,852 shares of the company's stock valued at $514,000 after buying an additional 2,958 shares in the last quarter. 65.09% of the stock is currently owned by institutional investors.
Amphastar Pharmaceuticals Trading Up 2.8%
AMPH traded up $0.84 during midday trading on Friday, reaching $30.50. 494,895 shares of the company were exchanged, compared to its average volume of 642,582. The company has a debt-to-equity ratio of 0.80, a quick ratio of 2.21 and a current ratio of 3.29. Amphastar Pharmaceuticals, Inc. has a one year low of $20.39 and a one year high of $53.96. The stock has a market capitalization of $1.42 billion, a P/E ratio of 11.42 and a beta of 0.76. The stock's 50-day simple moving average is $24.10 and its 200 day simple moving average is $25.82.
Analyst Ratings Changes
A number of analysts have recently weighed in on the company. JPMorgan Chase & Co. restated a "neutral" rating and issued a $30.00 target price (down from $45.00) on shares of Amphastar Pharmaceuticals in a research note on Monday, May 12th. Piper Sandler decreased their price target on Amphastar Pharmaceuticals from $30.00 to $25.00 and set a "neutral" rating on the stock in a report on Friday, August 8th. Wells Fargo & Company decreased their price target on Amphastar Pharmaceuticals from $40.00 to $35.00 and set an "overweight" rating on the stock in a report on Thursday, May 8th. Finally, Needham & Company LLC upgraded Amphastar Pharmaceuticals from a "hold" rating to a "buy" rating and set a $36.00 price target on the stock in a report on Tuesday, August 12th. Two investment analysts have rated the stock with a Buy rating and two have assigned a Hold rating to the company's stock. Based on data from MarketBeat.com, the company currently has a consensus rating of "Moderate Buy" and an average price target of $31.50.
Check Out Our Latest Research Report on Amphastar Pharmaceuticals
Amphastar Pharmaceuticals Company Profile
(
Free Report)
Amphastar Pharmaceuticals, Inc, a bio-pharmaceutical company, develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States, China, and France. It offers BAQSIMI, a nasal spray for the treatment of severe hypoglycemia; Primatene Mist, an over-the-counter epinephrine inhalation product for the temporary relief of mild symptoms of intermittent asthma; Enoxaparin, to prevent and treat deep vein thrombosis; REXTOVY and Naloxone for opioid overdose; Glucagon for injection emergency kit; and Cortrosyn, for use as a diagnostic agent in the screening of patients with adrenocortical insufficiency.
Featured Articles
Before you consider Amphastar Pharmaceuticals, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Amphastar Pharmaceuticals wasn't on the list.
While Amphastar Pharmaceuticals currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
MarketBeat All Access